Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT05005728 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT05005728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05005728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Xencor, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 22, 2021
Completion date
June 10, 2025
Enrollment
72 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer